Skip to content
ES
MARKETS / NASDAQ / CYRX
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Cryoport, Inc. CYRX

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$176.2M
▲ 12.4% YoY
$78.3M
$-25.0M
In brief

What this company does

Cryoport, Inc. provides integrated, temperature-controlled supply chain solutions for the life sciences, with a focus on supporting the cell and gene therapy market. As of December 31, 2025, Cryoport supported 760 clinical trials and 20 commercially approved cell and gene therapies. The Company delivers its integrated life sciences services and products through three operating units. Cryoport Systems provides temperature-controlled BioLogistics, BioServices, and cryopreservation solutions, supporting clinical and commercial workflows through specialized transport, cGMP storage, kit production, labeling, packaging, and commercial therapy fulfillment. CryoGene delivers long-term temperature-controlled BioStorage and related value-added services for preclinical and early-stage clinical programs for biopharmaceutical products. MVE Biological Solutions designs and manufactures cryogenic systems, including freezers, dewars, and transport systems, used for the storage and movement of biological materials in the life sciences.

Written from the business description in Cryoport, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.

Growth
USD 176.2M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 176.2 · Net income 78.3
80M160M-100M-200M201020122014201620182020202220242025
Compound annual growth
−9.4%
+17.5%
+40.5%
+48.3%
−45.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +17.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
44 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -20.9% · Net 44.4%
-500%-1000%201020122014201620182020202220242025
ROE
FY2025 · ROE 17.3%
-200%-400%-600%201020122014201620182020202220242025
Gross margin47.1%
Operating margin-20.9%
Net margin44.4%
Return on assets10.7%
EBITDAUSD -9.1M

Each USD of equity produced 17 cents of profit this year.

Cash & shareholders
USD 6.0M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -25.0
-20M201020122014201620182020202220242025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 6.0
20M-10M-20M2020202120222025
Dividends paid—
Net buybacksUSD 6.0M
Share of profit7.7%
Consecutive raises—

USD 6.0M in buybacks — 8% of the year's profit went back to shareholders.

Total assetsUSD 765.0M
EquityUSD 502.6M
CashUSD 250.5M
Current ratio2.17×

Equity funds 66% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.20.20.20.20.20.10.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.1−0.1−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.0−0.00.00.00.00.00.00.00.00.00.00.0
Net income $B0.1−0.1−0.1−0.0−0.3−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $1.40−2.49−2.21−0.93−6.18−1.94−0.55−0.34−0.34−0.93−2.05−2.44−4.81−0.17−0.27−0.46
Dividend / sh $················
Payout %················
ROE %17.3−25.8−19.1−6.2−53.8−12.8−22.2−33.9−67.0−298.8−733.0··−766.1−161.9−103.4
Shares out B0.050.050.050.050.050.040.040.030.030.020.010.010.000.040.040.03

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 80 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 15 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
Data on record since2010

Share this section

Download image